| CMVLF Stock | | | USD 1.25 0.00 0.00% |
Director
Dr. David J.D. Sourdive was Director, Executive Vice President Technical Operations, Member of Executive Committee and Deputy Chief Executive Officer at Cellectis SA since 2016. Previously he served as Company Executive Vice PresidentCorporationrate Development and Director. From 2014, Dr. Sourdive also served on the Board of Directors of Mediterranean Institute for Life Sciences. He previously served on the Board of Directors of Medicen Paris Region and Seine Saint Denis Avenir. From 1998 to 2000, he directed the biotechnologies laboratory of the Centre dEtudes du Bouchet for the French Ministry of Defense since 2016.
| Age | 56 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Phone | 33 1 81 69 16 00 |
| Web | https://www.cellectis.com |
Sourdive graduated from the Ecole Polytechnique and received his Ph.D. in molecular virology at the Institut Pasteur. He also has management training from the HEC . He is currently on the Board of Directors within MEDILS, Eukarys SAS and Omics SAS.
Cellectis Management Efficiency
The company has return on total asset
(ROA) of
(0.2408) % which means that it has lost $0.2408 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.557) %, meaning that it generated substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities.
Cellectis SA has accumulated 18.77
M in total debt with debt to equity ratio
(D/E) of 0.52, which is about average as compared to similar companies. Cellectis SA has a current ratio of 3.11, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Cellectis until it has trouble settling it off, either with new capital or with free cash flow. So, Cellectis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cellectis SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cellectis to invest in growth at high rates of return. When we think about Cellectis' use of debt, we should always consider it together with cash and equity.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis Romainvil operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 294 people. Cellectis SA [CMVLF] is a
Pink Sheet which is traded between brokers over the counter.
Management Performance
Cellectis SA Leadership Team
Elected by the shareholders, the Cellectis' board of directors comprises two types of representatives: Cellectis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cellectis. The board's role is to monitor Cellectis' management team and ensure that shareholders' interests are well served. Cellectis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cellectis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andre Choulika, Chairman of the Board and CEO, Member of the Executive Committee | |
| MarieBleuenn Terrier, General Counsel, Member of the Executive Committee | |
| Dr MBA, Chief Officer | |
| David Sourdive, Co-Founder, Executive VP of Corporate Devel. and Director | |
| Valerie Cros, Principal Officer | |
| Kyung NamWortman, Ex Officer | |
| Philippe Duchateau, Chief Scientific Officer | |
| Pascalyne Wilson, Director Communications | |
| Jean Epinat, Chief Officer | |
| MSc MSc, Chief Officer | |
Cellectis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Cellectis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Cellectis Pink Sheet
When determining whether Cellectis SA is a strong investment it is important to analyze Cellectis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cellectis'
future performance.
For an informed investment choice regarding Cellectis Pink Sheet, refer to the following important reports: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectis SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in bureau of economic analysis.
You can also try the
Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Please note, there is a significant difference between Cellectis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.